GlassScriptPhysician profile
Stephen Pearce Scorey
NPI 1851778427
$3,464.64
in general payments reported to CMS, 2019-2025
34 companies · $839 in 2025
The $839 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $179 · 2021: $16.40 · 2022: $460 · 2023: $449 · 2024: $927 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,214.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $636.05 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $458.69 | 2022-2025 | Qulipta, Viberzi, Linzess |
| Astrazeneca Pharmaceuticals LP | $367.70 | 2019-2025 | Farxiga, Airsupra, Andexxa |
| Pfizer INC. | $267.57 | 2019-2025 | |
| Abbott Laboratories | $206.99 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $174.28 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.01 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $118.21 | 2024-2025 | Arexvy, Shingrix |
| Astellas Pharma US INC | $118.19 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.81 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $70.39 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $62.09 | 2019-2020 | |
| Medtronic, INC. | $59.81 | 2023-2025 | Inceptiv, Intellis Adaptivestim, Accurian |
| Xeris Pharmaceuticals, INC. | $54.65 | 2024-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $53.41 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $53.00 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $49.52 | 2023-2025 | Eliquis |
| Ironwood Pharmaceuticals, INC | $48.78 | 2024-2025 | |
| Lilly USA, LLC | $47.73 | 2019-2022 | |
| Inspire Medical Systems, INC. | $46.78 | 2024-2025 | Inspire |
| Dexcom, INC. | $43.84 | 2022-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $42.58 | 2022 | |
| Exact Sciences Corporation | $28.47 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $27.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $25.30 | 2020 | |
| Corium, LLC | $24.24 | 2024 | Azstarys |
| Antares Pharma, INC. | $23.40 | 2023 | Nocdurna, Tlando, Xyosted |
| Biohaven Pharmaceutical Holding Company LTD. | $20.85 | 2022 | |
| Sage Therapeutics, LLC | $18.38 | 2024 | |
| Aytu Biopharma, INC. | $18.37 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.30 | 2024 | |
| Idorsia Pharmaceuticals US INC | $17.13 | 2023 | Quviviq |
| Halozyme INC | $15.76 | 2023 | |
| Phathom Pharmaceuticals, INC. | $15.45 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Scorey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.